Caprotec Bioanalytics to Showcase New Stauro caproKit for Signal Transduction Research and Drug Development at HUPO 2009

Caprotec bioanalytics GmbH announced the commercial launch of its Stauro caproKit, enabling the discovery, identification and characterization of proteins interacting with staurosporine.

Staurosporine. originally isolated from the bacterium Streptomcyes staurosporeus, is a potent inhibitor of many protein kinases and widely used for research purposes, e.g. as an inducer of apoptosis, the process of programmed cell death.

"The Stauro caproKit is a new and innovatice tool for researchers interested in analyzing the kinome in complex biological samples" stated Dr. Hubert Koster, CEO of caprotec bioanalytics. "Our date demonstrates that the Stauro caproKit provides a significant reduction of sample complexity with the associated benefitcs for mass spectrometric protein identification."

The Stauro caproKit represents the third kit launch this year for caprotec, the first two being the SAH caproKit to investigate SAM/SAH binding proteins, and the cAMP caproKit to investiage cAMP/PKA/AKAP-dependent signal transduction. Each of the company's caproKits are based on caprotec's proprietary Capture Compound Mass Spectometry (CCMS) technology, a novel and direct way to investigate small molecule - protein interactions resulting in a significant functional reduction of proteome complexity. Capture Compounds enable the direct isolation and identification of proteins including membrane proteins out of any complex biological sample. The product provides ample flexibility in terms of starting material and up- and downstream processed, allowing for an easy integration in existing protocols.